Marcella
Bassetto¶
*,
Salvatore
Ferla¶
,
Gilda
Giancotti
,
Fabrizio
Pertusati
,
Andrew D.
Westwell
,
Andrea
Brancale
and
Christopher
McGuigan
School of Pharmacy and Pharmaceutical Sciences, Redwood Building, King Edward VII Avenue, CF10 3NB, Cardiff, Wales, UK. E-mail: BassettoM@cardiff.ac.uk
First published on 26th May 2017
Prostate cancer is a major cause of male death worldwide and the identification of new efficient treatments is constantly needed. Different non-steroidal androgen receptor antagonists are approved also in the case of castration-resistant cancer forms. Using a rational approach and molecular modelling studies to modify the structure of antiandrogen drug bicalutamide, a new series of phenylsulfonyl-benzamide derivatives was designed and synthesised. Their antiproliferative activities were evaluated in four different human prostate cancer cell lines and several new compounds showed significantly improved IC50 values in the low μM range. The cytotoxicity profile was also evaluated for the novel structures in the HEK293 cell line.
One of the most common mutations found for bicalutamide is W741L in helix 12 of the receptor,3 which allows the protein to adopt its closed agonist conformation even in the presence of the antagonist: with this mutation, due to some residual structural flexibility in 1, ring B can bend to occupy an inner portion of the ligand-binding domain, thus allowing the closure of the receptor into its agonist conformation. Treatment with enzalutamide induces instead a F876L mutation in the AR, which also confers an antagonist to agonist switch in activity for the drug.4 Second-generation antiandrogen ARN-509 (Fig. 1), which is now in Phase III clinical trials,5 is also associated with the insurgence of resistance through the F876L mutation,6 while new-generation AR inhibitor ODM-201 (Fig. 1), now in Phase III trials, has shown retained activity in the F876L AR mutant.7
Most non-steroidal antiandrogens are structurally characterised by two differently substituted aromatic rings, named ring A and ring B, connected by a linker, either linear (bicalutamide-like compounds) or cyclic (enzalutamide-like compounds) (Fig. 1).8 Recently, a novel 4-(4-benzoylaminophenoxy) phenol antiandrogen scaffold (4), derived from the natural pigment curcumin, has been reported, in which a central phenyl group is acting as linker connecting two different aromatic rings.9
With the aim to rigidify the structure of bicalutamide and obtain new anticancer agents, we designed a novel molecular scaffold in which we replaced the flexible bicalutamide methyl-hydroxy-methylene linker with a rigid phenyl group, maintaining the two lateral aromatic rings commonly found in antiandrogen compounds (Fig. 2). Moreover, following an approach previously proven successful in our research group for increasing bicalutamide and enzalutamide anti-prostate cancer activity,10,11 different perfluoro groups were systematically inserted in aromatic ring B (R2 substituent), replacing the classical 4-cyano substituent. The phenolic 4-hydroxy group of 4, previously reported as essential for AR antagonistic activity,9 was either maintained, in order to evaluate its importance for anti-prostate cancer effect, or replaced with a 3-trifluoromethyl group, as a means to incorporate and evaluate one of the most successful modifications we have previously found in other series of related compounds.10,11
Following this approach, a novel family of phenylsulfonyl-benzamides was developed (Fig. 2), and their potential anti prostate cancer activity was evaluated in four different human prostate cancer cell lines, together with their cytotoxicity in the HEK293 cell line.
Fig. 4A shows the docking results found for 13a in the ligand binding domain (LBD) of the open AR homology model, obtained using Plants docking software.13 The extra phenyl ring, as observed in the flexible alignment results, maintains the molecule in a rigid extended conformation that entirely occupies the binding site, similarly to bicalutamide and enzalutamide. The phenolic hydroxyl group is facing outside the binding groove, therefore its replacement with other functions is predicted to be tolerated. Docking results for 13a in the bicalutamide-resistant AR mutant W741L crystal structure (PDB ID 1Z95),3 which corresponds to the closed active conformation of the receptor, indicate that, due to its increased rigidity, the novel molecule cannot fit the AR antagonist conformation, as highlighted by the steric clashes between 13a and helix 12 (Fig. 4B). These results suggest that the novel scaffold could maintain its antagonist activity also in the presence of the W741L mutation.
Fig. 4 A) Predicted binding mode of 13a (carbon atoms in light blue) in the AR homology model.10 The compound occupies the LBD in a similar way to bicalutamide (carbon atoms in purple). B) 13a in the bicalutamide-W741I AR closed conformation crystal structure 1Z95 (B).3 The compound shows major clashes (purple surface), highlighted by red circles, with the protein surface (in grey) of the closed AR structure, especially with helix 12, indicating that it might impede the AR closure even in the presence of adaptive mutations. |
In the first step a copper catalysed C–S coupling reaction was used for the preparation of intermediates 8–9. The conditions for this step were optimised from a reported procedure.14 After 12 hours reflux as in the published protocol, 4-iodobenzoic acid 7 was still present in the reaction mixture. No difference could be observed with a prolonged reaction time, while total consumption of starting material 7 was finally achieved by doubling the equivalents of thiophenol and base. The new conditions were applied to react differently substituted thiophenols 5–6 with 4-iodobenzoic acid 7 for 24 hours in water, giving the desired different substituted phenylthio-benzoic acids in an almost quantitative yield. Amides 11a–i and 12a, h were obtained reacting the corresponding anilines 10a–i with 8 and 9 in the presence of thionyl chloride in DMA, modifying a literature procedure.15 In the last step, sulphur derivatives 11a–i and 12a, h were oxidized to the corresponding sulfones 13a–i and 15a, h using mCPBA at 25 °C.10 In two cases, the corresponding product of sulphur partial oxidation was also isolated (14e and 14i). These two sulfoxides were characterised by low solubility in the reaction solvent, therefore complete oxidation to the corresponding sulfone was much slower and did not go to completion within the reaction time. Using this synthetic approach, 24 novel phenylsulfonyl-benzamides derivatives were prepared, purified and fully characterised.
Standard bicalutamide and enzalutamide were also prepared following reported procedures.10
Compound | R1 | X | R2 | Absolute IC50 (μM) | ||||
---|---|---|---|---|---|---|---|---|
22Rv1 | DU-145 | LNCaP | VCaP | Geo. mean | ||||
Bicalutamide | — | — | — | 49.58 | 49.20 | 45.27 | 68.37 | 52.42 |
Enzalutamide | — | — | — | 24.77 | 44.55 | 20.90 | 24.47 | 27.41 |
11a | 4-OH | S | 4-CN, 3-CF3 | 6.24 | 7.77 | 5.43 | 9.55 | 7.08 |
11b | 4-OH | S | 4-NO2, 3-CF3 | 4.50 | 5.74 | 3.58 | 5.19 | 4.68 |
11c | 4-OH | S | 3,5-CF3 | 3.35 | 5.60 | 2.39 | 2.59 | 3.28 |
11d | 4-OH | S | 2,5-CF3 | 10.34 | 16.63 | 11.42 | 10.88 | 12.09 |
11e | 4-OH | S | 4-SF5 | 3.71 | 6.76 | 4.86 | 7.15 | 5.43 |
11f | 4-OH | S | 3-SF5 | 2.94 | 4.35 | 3.32 | 6.10 | 4.01 |
11g | 4-OH | S | 4-CF3 | 6.23 | 8.55 | 8.30 | 9.68 | 8.09 |
11h | 4-OH | S | 3-CF3 | 5.73 | 5.95 | 9.66 | 10.58 | 7.69 |
11i | 4-OH | S | 2-CF3 | 30.92 | 35.68 | 11.43 | 32.27 | 25.25 |
12a | 3-CF3 | S | 4-CN, 3-CF3 | 3.57 | 5.12 | 8.87 | 5.66 | 5.50 |
12h | 3-CF3 | S | 3-CF3 | 6.96 | 9.89 | 12.47 | 28.22 | 12.47 |
13a | 4-OH | SO2 | 4-CN, 3-CF3 | 12.08 | 12.62 | 4.68 | 8.56 | 8.84 |
13b | 4-OH | SO2 | 4-NO2, 3-CF3 | 7.30 | 8.85 | 4.96 | 8.57 | 7.24 |
13c | 4-OH | SO2 | 3,5-CF3 | 6.44 | 9.92 | 8.41 | 9.72 | 8.50 |
13d | 4-OH | SO2 | 2,5-CF3 | 20.66 | 27.79 | 23.18 | 30.48 | 25.24 |
13e | 4-OH | SO2 | 4-SF5 | 5.78 | 10.85 | 2.49 | 5.35 | 5.37 |
14e | 4-OH | SO | 4-SF5 | 5.60 | 11.02 | 0.90 | 3.53 | 3.75 |
13f | 4-OH | SO2 | 3-SF5 | 5.66 | 6.01 | 3.98 | 10.81 | 6.18 |
13g | 4-OH | SO2 | 4-CF3 | 16.79 | 30.69 | 10.75 | 27.16 | 19.69 |
13h | 4-OH | SO2 | 3-CF3 | 15.06 | 17.73 | 10.19 | 30.08 | 16.84 |
13i | 4-OH | SO2 | 2-CF3 | 49.31 | 45.88 | 39.31 | 65.20 | 49.07 |
14i | 4-OH | SO | 2-CF3 | 100.00 | 100.00 | 61.98 | 97.60 | 88.19 |
15a | 3-CF3 | SO2 | 4-CN, 3-CF3 | 3.57 | 4.70 | 3.73 | 7.87 | 4.71 |
15h | 3-CF3 | SO2 | 3-CF3 | n.d | n.d | n.d | n.d | n.d |
Considering their overall profile in the four cell lines (geometric mean), almost all the new derivatives performed significantly better than bicalutamide, improving its effect up to 16-fold. The new inhibitors showed concentration-dependent activity with mean IC50 values ranging from 3.2 μM to >100 μM. Compared with standard enzalutamide, antiproliferative effect was improved up to 8-fold.
Substituent R1 in ring B does not seem to influence the anticancer profile of the scaffold, as no substantial differences were found between the OH group in the para position or the CF3 in meta (i.e.11avs.12a). This finding is in accordance with the proposed binding mode for 13a, in which the R1 substituent is facing outside the AR binding domain without making specific interactions.
In both our previous work on bicalutamide derivatives and in another published work on analogues of SARMs (selective androgen receptor modulators),10,16 thioether compounds (X = S) are associated with better antiproliferative activities than the corresponding sulfones (X = SO2), with a decrease of effect in the sulfones up to 8-fold. In the new scaffold presented in this work, no particular differences can be observed between thioether and sulfone compounds, with retained activity in most sulfones (i.e.11avs.13a) and only a small increase of IC50 values up to 2-fold in few cases (i.e.11cvs.13c). The partially oxidized derivatives (X = SO) retain the effect of the corresponding thioethers and sulfones (i.e.11e and 13evs.14e).
Removal of the CN or the NO2 group in the para position of ring B is associated with retained activity, as found for mono 3-CF3 derivative 11h. Moving the trifluoromethyl group from meta to para position does not have a significant effect on activity (i.e.11hvs.14g), whereas the ortho substitution is characterized by a 3-fold reduction of overall effect in the four cell lines (i.e.11hvs.11i). Replacing the trifluoromethyl group with a bigger –SF5 moiety in para or meta position is associated with a mildly improved activity profile (i.e.11gvs.14e).
Addition of an extra CF3 in meta (R2 = 3,5-CF3), gives the best results in terms of overall activity in the four cell lines (i.e.11a and 13hvs.14c), as we had similarly observed in our previous research efforts.10 Also in this case, moving one trifluoromethyl group from meta to ortho position is associated with activity reduction (i.e.11cvs.11d).
Examining each individual cell line, most of the new compounds showed the best results in the cell lines that highly express the androgen receptor. Among them, LNCaP cells were found to be the most sensitive to the new derivatives, with different compounds active at low μM concentrations and one reaching a sub μM IC50 value (14e). These data suggest that the newly prepared compounds are likely to retain an antagonistic effect on the androgen receptor. An interesting activity profile was also found in the DU-145 cell line (the least sensitive to our new molecules), which expresses low levels of the androgen receptor19 and is insensitive to androgen activity. The same effect can be observed also for parent bicalutamide (similar IC50 values across the four cell lines), suggesting that besides its canonical anti-androgen receptor action, a different antiproliferative mechanism could also be involved. The new phenylsulfonyl-benzamides, in addition to potentially increase the antagonistic activity on the AR, might also enhance the potential off target effect, even though in some cases they seem more selective for androgen-sensitive cell lines than bicalutamide (i.e.13e, 14e, 13g). As a general observation, the improved antiproliferative activity of the novel compounds should be regarded as the result of the whole structure of each single derivative, since the data found appear to be a combination of the simultaneous effects of the substituent in ring B and linker X.
Footnotes |
† The authors declare no competing interests. |
‡ Electronic supplementary information (ESI) available. See DOI: 10.1039/c7md00164a |
§ This work is dedicated to the memory of Prof. Chris McGuigan, a great colleague and scientist, invaluable source of inspiration and love for research. |
¶ These authors contributed equally to this work. |
This journal is © The Royal Society of Chemistry 2017 |